Bayer's Experimental Drug Cuts Stroke Recurrence Risk by Twenty-Six Percent

A Breakthrough in Stroke Prevention

Bayer has announced landmark results from its Phase three OCEANIC-STROKE trial, showing that its experimental drug asundexian reduced the risk of recurrent ischemic stroke by twenty-six percent compared to placebo. The results, presented at the International Stroke Conference 2026 in New Orleans, mark the first successful late-stage trial of a Factor XIa inhibitor, a new class of blood thinners designed to prevent dangerous clots without the bleeding risks associated with current anticoagulants.

How the Trial Worked

The global study enrolled over twelve thousand patients across seven hundred sites in thirty-seven countries, all of whom had experienced a non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Patients taking fifty milligrams of asundexian once daily alongside standard antiplatelet therapy showed a statistically significant reduction in stroke recurrence. Crucially, major bleeding rates remained virtually identical between the treatment and placebo groups, at one point nine percent versus one point seven percent.

Why It Matters

Nearly one in four stroke survivors will experience another stroke, making secondary prevention a critical unmet medical need. Current treatments rely on antiplatelet drugs like aspirin and clopidogrel, which reduce recurrence but carry bleeding risks that limit their effectiveness. Asundexian works differently by targeting Factor XIa, a protein involved in harmful clot formation but not in the body's natural wound-healing process.

Competitive Landscape and Path Forward

The results come at a pivotal moment for the Factor XIa inhibitor class. Rivals Bristol Myers Squibb and Johnson and Johnson halted their own Phase three trial of competing drug milvexian for acute coronary syndrome in late 2025 after it failed to meet its primary endpoint. Bayer's success validates the approach and positions asundexian as a potential blockbuster, with analysts projecting annual sales exceeding one billion dollars. The drug already holds FDA Fast Track designation, and Bayer plans to engage with regulators globally to pursue marketing authorisation.